Cite
Ammari S, Sallé de Chou R, Assi T, et al. Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab. Diagnostics (Basel). 2021;11(7)doi: 10.3390/diagnostics11071263.
Ammari, S., Sallé de Chou, R., Assi, T., Touat, M., Chouzenoux, E., Quillent, A., Limkin, E., Dercle, L., Hadchiti, J., Elhaik, M., Moalla, S., Khettab, M., Balleyguier, C., Lassau, N., Dumont, S., & Smolenschi, C. (2021). Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab. Diagnostics (Basel, Switzerland), 11(7), . https://doi.org/10.3390/diagnostics11071263
Ammari, Samy, et al. "Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab." Diagnostics (Basel, Switzerland) vol. 11,7 (2021). doi: https://doi.org/10.3390/diagnostics11071263
Ammari S, Sallé de Chou R, Assi T, Touat M, Chouzenoux E, Quillent A, Limkin E, Dercle L, Hadchiti J, Elhaik M, Moalla S, Khettab M, Balleyguier C, Lassau N, Dumont S, Smolenschi C. Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab. Diagnostics (Basel). 2021 Jul 14;11(7). doi: 10.3390/diagnostics11071263. PMID: 34359346; PMCID: PMC8305059.
Copy
Download .nbib